You need JavaScript to view this

Report on the 2{sup nd} Research Coordination Meeting on The Development of Therapeutic Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide. Working Document

Abstract

Radionuclide therapy is practiced for the treatment of malignant disorders of various organs and tissues as well as for treating certain other diseases such as rheumatoid arthritis. Advances in understanding tumor biology as well as developments in peptide chemistry and monoclonal antibody technology are opening new opportunities for the development of therapeutic radiopharmaceuticals, thereby widening the scope of radionuclide therapy. In addition, particulate based radiopharmaceuticals are useful for treating hepatocarcinoma as well as in radiation synovectomy. With the establishment of new products the demand and application of therapeutic nuclear medicine is expected to grow rapidly. While there are a large number of radioisotopes proposed for targeted therapy, practical considerations had been limiting the number of usable isotopes. Generator-produced radionuclides are an attractive option for the large scale on-site availability of therapeutic isotopes. The IAEA’s CRP on the ‘Development of generator technologies for therapeutic radionuclides’ (2004-2007) was successful in developing technologies for the preparation of {sup 188}W/{sup 188}Re and {sup 90}Sr/{sup 90}Y generators for eluting {sup 188}Re and {sup 90}Y of high radionuclidic and chemical purity usable for research applications in the development of therapeutic radiopharmaceuticals. The IAEA’s CRP on ‘The development of therapeutic radiopharmaceuticals based on {sup 188}Re and {sup  More>>
Authors:
"NONE"
Publication Date:
Jul 01, 2010
Product Type:
Conference
Report Number:
IAEA-RC-1088.2
Resource Relation:
Conference: 2. Research Coordination Meeting on The Development of Therapeutic Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy, Vienna (Austria), 22-26 Mar 2010; Other Information: Refs., figs., tabs., diagrams
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; IAEA; MEETINGS; MONOCLONAL ANTIBODIES; NEOPLASMS; PEPTIDES; QUALITY CONTROL; RADIOPHARMACEUTICALS; RADIOTHERAPY; RECOMMENDATIONS; REVIEWS; RHENIUM 188; RHEUMATIC DISEASES; STRONTIUM 90; TUNGSTEN 188; YTTRIUM 90
OSTI ID:
22270088
Research Organizations:
International Atomic Energy Agency, Division of Physical and Chemical Sciences, Vienna (Austria)
Country of Origin:
IAEA
Language:
English
Other Identifying Numbers:
TRN: XA14M3056091320
Availability:
Available from INIS in electronic form. Also available on-line: http://www-naweb.iaea.org/napc/iachem/meetings/RCMs/RC-1088-2_report_complete.pdf
Submitting Site:
INIS
Size:
185 page(s)
Announcement Date:
Oct 22, 2014

Citation Formats

Report on the 2{sup nd} Research Coordination Meeting on The Development of Therapeutic Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide. Working Document. IAEA: N. p., 2010. Web.
Report on the 2{sup nd} Research Coordination Meeting on The Development of Therapeutic Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide. Working Document. IAEA.
2010. "Report on the 2{sup nd} Research Coordination Meeting on The Development of Therapeutic Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide. Working Document." IAEA.
@misc{etde_22270088,
title = {Report on the 2{sup nd} Research Coordination Meeting on The Development of Therapeutic Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide. Working Document}
abstractNote = {Radionuclide therapy is practiced for the treatment of malignant disorders of various organs and tissues as well as for treating certain other diseases such as rheumatoid arthritis. Advances in understanding tumor biology as well as developments in peptide chemistry and monoclonal antibody technology are opening new opportunities for the development of therapeutic radiopharmaceuticals, thereby widening the scope of radionuclide therapy. In addition, particulate based radiopharmaceuticals are useful for treating hepatocarcinoma as well as in radiation synovectomy. With the establishment of new products the demand and application of therapeutic nuclear medicine is expected to grow rapidly. While there are a large number of radioisotopes proposed for targeted therapy, practical considerations had been limiting the number of usable isotopes. Generator-produced radionuclides are an attractive option for the large scale on-site availability of therapeutic isotopes. The IAEA’s CRP on the ‘Development of generator technologies for therapeutic radionuclides’ (2004-2007) was successful in developing technologies for the preparation of {sup 188}W/{sup 188}Re and {sup 90}Sr/{sup 90}Y generators for eluting {sup 188}Re and {sup 90}Y of high radionuclidic and chemical purity usable for research applications in the development of therapeutic radiopharmaceuticals. The IAEA’s CRP on ‘The development of therapeutic radiopharmaceuticals based on {sup 188}Re and {sup 90}Y for radionuclide therapy’ was formulated to focus on enhancing the capacity of the {sup 90}Sr/{sup 90}Y generator; to develop and validate quality control methods for the generator eluate; and to develop therapeutic radiopharmaceuticals based on {sup 188}Re and {sup 90}Y. The first RCM of the CRP was held in Polatom, Warsaw, Poland from 30 June to 4 July 2008. The meeting reviewed the work going on in the different participating laboratories, and the facilities, expertise and capabilities of the different participating groups, and formulated the work plan of the CRP. The work plan for the first 18 months of the CRP had three main components, which were split into several subprojects. The meeting report which was prepared post RCM and circulated among the participants gives details about the projects identified to be implemented during the CRP, the rationale for identification of the projects and a detailed work plan. During the RCM, subproject coordinators were identified with responsibility to liaise among the participating groups and monitor the progress of each sub project. An overall coordinator of the CRP was designated, whose responsibility was to liaise with the subproject coordinators. The overall coordinator was also to make six monthly reports on the progress of the CRP. The two six monthly reports thus prepared were circulated among all the CRP participants in order to disseminate the details of the work done in each laboratory. The second RCM of the CRP was held from 22 to 26 March 2010 at IAEA Head Quarters in Vienna. The purpose of the meeting was to review the progress of the work done in the first 18 months; to make necessary mid term corrections on the CRP’s implementation and to formulate the work plan for the second half of the CRP. This report gives the summary of the work done in each participating laboratory, the overall achievements in the first 18 months of the CRP, the work plan for the second part of the CRP as well as recommendations to the IAEA, detailing the participants’ inputs, for the implementation of the CRP.}
place = {IAEA}
year = {2010}
month = {Jul}
}